ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Roche to buy Ignyta for $1.7 billion
pharmatimes
January 03, 2018Roche has announced plans to buy US group Ignyta for $27 a share in an all-cash deal totaling around $1.7 billion, securing itself access to the latter’s experimental cancer medicines. -
Roche to Acquire Ignyta in $1.7B Deal
contractpharma
December 28, 2017Roche?has entered an agreement to acquire?Ignyta, Inc., a U.S. based pharmaceutical company focused on developing cancer therapies,?for $1.7 billion. The acquisition expands Roche’s oncology portfolio globally. -
Roche and Ignyta signs merger agreement
biospectrumasia
December 26, 2017The merger agreement has been unanimously approved by the boards of Ignyta and Roche -
Ignyta's cancer drug entrectinib receives FDA orphan drug status
pharmaceutical-technology
July 12, 2017Biotechnology firm Ignyta has received orphan drug designation from the US Food and Drug Administration (FDA) for its investigational, orally available, CNS-active tyrosine kinase inhibitor, entrectinib, to treat NTRK fusion-positive solid tumours.
Pharma Sources Insight January 2025
